Research program Live corpus

Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.

PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,405 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers

40,405 Papers indexed

1,440 Papers AI scored

40,405 Ranked papers

100.0% Coverage

Featured discovery ● Live

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

AI Score 79.80 Active signal

Grade A

Final score 88.16

Narrative velocity Not calculated

Confidence Building

CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.

Read full analysis →

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE

↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing

TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Published Jun 20, 2026

Journal Trials

88.16 Ranking score

A grade PMID 42321916

View analysis →

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Published Sep 03, 2026

Journal JAMA oncology

87.88 Ranking score

A grade PMID 42690647

View analysis →

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Published Jul 01, 2026

Journal The Lancet. Oncology

87.73 Ranking score

A grade PMID 42372741

View analysis →

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.

Published May 30, 2026

Journal Oncoimmunology

87.38 Ranking score

A grade PMID 42216567

View analysis →

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Published Mar 31, 2026

Journal BMJ (Clinical research ed.)

87.15 Ranking score

A grade PMID 41916649

View analysis →

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Published May 18, 2026

Journal EClinicalMedicine

86.97 Ranking score

A grade PMID 42382416

View analysis →

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Published May 18, 2026

Journal The Lancet. Child & adolescent health

85.99 Ranking score

A grade PMID 42150584

View analysis →

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Published Sep 17, 2026

Journal The New England journal of medicine

85.54 Ranking score

B grade PMID 42748428

View analysis →

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

Published Feb 20, 2026

Journal bioRxiv : the preprint server for biology

85.22 Ranking score

A grade PMID 41756844

View analysis →

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Published Sep 21, 2026

Journal Blood cancer discovery

85.08 Ranking score

A grade PMID 42765973

View analysis →

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Published Jun 26, 2026

Journal Cancer letters

85.07 Ranking score

A grade PMID 42362103

View analysis →

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Published Jul 14, 2026

Journal Blood advances

84.86 Ranking score

A grade PMID 42101908

View analysis →

LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-13 10:15 AM

1 Interventions to reduce paediatric cancer treatment abandonment in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet. Global health — Nov 13, 2026 2 Paediatric cancer treatment abandonment: multifaceted solutions required. The Lancet. Global health — Nov 13, 2026 3 Enteral Clonidine for the Management of Rigors in Pediatric Oncology. Journal of palliative medicine — Nov 13, 2026 4 Real-world implementation of optic pathway glioma surveillance in children with neurofibromatosis type 1: a 20-year cohort study. The British journal of ophthalmology — Nov 13, 2026 5 Pediatric-type Follicular Lymphoma Shows Unique Immunogenetic Features With Lack of Acquired N-glycosylation Sites. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc — Nov 13, 2026 6 Epigenetic Divergence Distinguishes Molecularly and Histologically Distinct Subtypes of Small Cell Carcinoma of the Ovary Hypercalcemic Type. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc — Nov 13, 2026 7 Radiation in Spine Care: A Comprehensive Review of Radiation Sources, Emerging Technology, Cancer Risk, and Radiation Stewardship. The spine journal : official journal of the North American Spine Society — Nov 13, 2026 8 Polycyclic Aromatic Hydrocarbons in Urban Motor-Park Soils of Asaba, Nigeria: Environmental Contamination, Source Characterization, and Human Health Risk. Environmental pollution (Barking, Essex : 1987) — Nov 13, 2026

WHAT THE AI SEES TODAY

Live pediatric oncology intelligence

● Live

↗

Therapeutic signal strength is updating across newly scored pediatric oncology literature.

✦

Mechanism clusters are forming around tumor biology, immune response, targeted therapy, treatment resistance, and drug repurposing.

⌁

Daily literature intake feeds the ranking engine and refreshes study-design, human-relevance, and therapeutic-relevance scores.

●

40,405 pediatric cancer records are currently visible under this search.

PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40405 results

A drug-diet combination could improve childhood cancer treatment.

PMID 40993410 Published: 2025-10-01 Ingested: 2026-08-02 12:05 AM Nature

AI -

Standard 33.9

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.9/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 37.0; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.

PMID 39316646 Published: 2024-12-12 Ingested: 2026-08-02 12:03 AM Blood

AI -

Standard 33.9

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.9/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 90.0; abstract quality: 40.0.

A Rare Laryngeal Schwannoma in an 11-Year-Old Boy.

PMID 36866713 Published: 2023-03-03 Ingested: 2026-08-02 12:04 AM Ear, nose, & throat journal

AI -

Standard 33.9

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.9/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 65.0; abstract quality: 65.0.

A Rare Cause of Chronic Leg Ulcer in Childhood: Parkes-Weber Syndrome.

PMID 35098773 Published: 2022-01-31 Ingested: 2026-08-02 12:03 AM The international journal of lower extremity wounds

AI -

Standard 33.9

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.9/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 65.0; abstract quality: 65.0.

Minimal Disseminated Disease Continues to Impact Outcomes Even in the Era of Targeted Therapy in Childhood ALK+ Anaplastic Large Cell Lymphoma, What More Do We Have to Offer?

PMID 41445897 Published: 2024-07-10 Ingested: 2026-08-02 12:04 AM South Asian journal of cancer

AI -

Standard 33.52

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 45.1; sample size: 20.0; recency: 80.0; abstract quality: 0.0.

Tumour-anchored Purkinje-mediated ventricular tachycardia in a child with cardiac rhabdomyoma.

PMID 42958915 Published: 2026-10-30 Ingested: 2026-11-01 10:15 AM Cardiology in the young

AI -

Standard 33.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 15.0; sample size: 20.0; recency: 100.0; abstract quality: 40.0.

Glutathione synthetase deficiency: 10 years later.

PMID 41500709 Published: 2026-01-07 Ingested: 2026-08-02 12:12 AM BMJ case reports

AI -

Standard 33.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 15.0; sample size: 20.0; recency: 100.0; abstract quality: 40.0.

Evaluation of EWSR1/FUS rearrangements by FISH and NKX2.2 immunoexpression in simple bone cysts of the jaw.

PMID 37891121 Published: 2023-08-01 Ingested: 2026-08-02 12:02 AM Oral surgery, oral medicine, oral pathology and oral radiology

AI -

Standard 33.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 65.0; abstract quality: 85.0.

Impact of Duffy-associated neutrophil count on maintenance chemotherapy management in a child with acute lymphoblastic leukemia.

PMID 39323046 Published: 2024-09-25 Ingested: 2026-08-02 12:02 AM Pediatric blood & cancer

AI -

Standard 33.44

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 39.7; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study.

PMID 39021218 Published: 2024-11-01 Ingested: 2026-08-02 12:03 AM Haematologica

AI -

Standard 33.44

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 39.7; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Therapy-Associated Lineage Switch and Clonal Evolution in Refractory NUP98::NSD1-Rearranged Acute Leukemia.

PMID 42757753 Published: 2026-09-18 Ingested: 2026-09-20 09:15 AM Pediatric blood & cancer

AI -

Standard 33.36

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 34.3; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

Relapsed childhood cancers show genomic scars left by previous therapy.

PMID 42527644 Published: 2026-07-29 Ingested: 2026-08-02 12:07 AM Nature

AI -

Standard 33.36

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 33.4/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 34.3; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

Page 3337 of 3368

Open the Research
Intelligence Map

Finding therapies hidden in 40,405 pediatric cancer papers.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Ranked Discovery Journal Articles

Database feed

All ranked pediatric cancer papers

AI-assisted research information

Open the Research Intelligence Map